Pheochromocytomas are catecholamine-secreting tumors arising from the adrenal medulla or rarely from other structures derived from neurocrest origin. Because biochemical evidence of catecholamine production usually precedes clinical manifestations, patients who have undergone resection of a pheochromocytoma are followed with serial monitoring of catecholamines. If urinary catecholamines are elevated, localization of recurrent and/or metastatic lesions is obtained by imaging procedures. Computed tomography and magnetic resonance imaging are useful techniques, but they do not provide specific metabolic information. Scintigraphy with metaiodobenzylguanidine (MIBG) labeled with either 123I or 131I is recommended for detection of metabolically active pheochromocytomas. However, a subset of these tumors are MIBG-negative. The 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) method has proven useful in the localization of neoplasms. The use of PET with both FDG and 82Rb (Rubidium) has been described in the localization of MIBG-negative suprarenal and thoracic pheochromocytomas. We report the utility of FDG-PET to detect pelvic recurrence of pheochromocytoma in an MIBG-negative patient.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism